| Literature DB >> 29500330 |
Mariëtte E C Waaijer1, David A Gunn2, Diana van Heemst1,3, P Eline Slagboom3,4, John M Sedivy5, Roeland W Dirks6, Hans J Tanke6, Rudi G J Westendorp7, Andrea B Maier8,9.
Abstract
Little is known on how well senescence markers in vitro and in situ correlate within individual donors. We studied correlations between the same and different in vitro markers. Furthermore, we tested correlations between in vitro markers with in situ p16INK4a positivity.From 100 donors (20-91 years), cultured dermal fibroblasts were assessed for reactive oxygen species (ROS), telomere-associated foci (TAF), p16INK4a and senescence-associated β-gal (SAβ-gal), with/ without 0.6 µM rotenone for 3 days (short-term). In fibroblasts from 40 donors, telomere shortening, ROS and SAβ-gal were additionally assessed, with/ without 20 nM rotenone for 7 weeks (long-term). In skin from 52 donors, the number of p16INK4a positive dermal cells was assessed in situ.More than half of the correlations of the same senescence markers in vitro between duplicate experiments and between short-term versus long-term experiments were significant. Half of the different senescence marker correlations were significant within the short-term and within the long-term experiments. The different senescence markers in vitro were not significantly correlated intra-individually with in situ p16INK4a positivity. In conclusion, the same and different senescence markers are frequently correlated significantly within and between in vitro experiments, but in vitro senescence markers are not correlated with p16INK4a positivity in situ.Entities:
Keywords: cellular senescence; correlation; in situ; in vitro; markers
Mesh:
Substances:
Year: 2018 PMID: 29500330 PMCID: PMC5842854 DOI: 10.18632/aging.101389
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Characteristics of donors.
| Young | Middle-aged | Old | |||||
| (N=10) | (N=80) | (N=10) | |||||
| Female, no.(%) | 7 (70.0) | 40 (50.0) | 6 (60.0) | ||||
| Age, years | 22.8 (1.5) | 63.2 (7.3) | 90.2 (0.5) | ||||
| Member of long-lived family | n/a | 40 (50.0) | n/a | ||||
| Body mass index, kg/m2 | 22.2 (1.8)a | 26.2 (4.1)b | 25.4 (3.8) | ||||
| Co-morbidities | |||||||
| Cerebrovascular accident | 0/10 (0.0) | 3/76 (3.9) | 2/10 (20.0) | ||||
| Chronic obstructive pulmonary disease | 0/10 (0.0) | 3/75 (4.0) | 1/10 (10.0) | ||||
| Diabetes mellitus | 0/10 (0.0) | 7/74 (9.5) | 2/10 (20.0) | ||||
| Hypertension | 0/10 (0.0) | 17/76 (22.4) | 5/10 (50.0) | ||||
| Malignancies | 0/10 (0.0) | 3/72 (4.2) | 1/10 (10.0) | ||||
| Myocardial infarction | 0/10 (0.0) | 0/75 (0.0) | 3/10 (30.0) | ||||
| Rheumatoid arthritis | 0/10 (0.0) | 0/76 (0.0) | 3/10 (30.0) | ||||
| Smoking, current | 0/10 (0.0) | 10/76 (13.2) | 1/10 (10.0) | ||||
SD: standard deviation. a: N=8, b: N=77. N/a: not applicable. Data are depicted as either mean (SD) or number (%). Diseases and intoxications are given as no./total known (%). * This subset was used for the correlation between in vitro senescence markers versus in situ p16INK4a positive human fibroblasts (3B).
Senescence markers and their correlations between duplicate short-term experiments (1A).
| Distribution of markers | ||||
| Experiment I | Experiment II | Correlation coefficient | P-value | |
| p16INK4a, % | 0.90 (0.45; 1.65) | 1.61 (0.76; 2.71) | 0.702 | <0.001 |
| TAF, %/nucleus | 24.2 (16.9; 31.0) | 24.4 (18.5; 32.1) | 0.418 | <0.001 |
| ROS, FI | 1477 (1280; 1706) | 1455 (1295; 1762) | -0.111 | 0.354 |
| SAβ-gal, FI | 2959 (2389; 3813) | 2987 (2187; 3951) | 0.527 | <0.001 |
| p16INK4a, % | 2.17 (1.10; 4.17) | 4.70 (2.33; 6.48) | 0.623 | <0.001 |
| TAF, %/nucleus | 20.6 (14.8; 27.9) | 21.9 (16.0; 26.7) | 0.414 | <0.001 |
| ROS, FI | 2003 (1734; 2376) | 1972 (1653; 2366) | 0.139 | 0.244 |
| SAβ-gal, FI | 4251 (3405; 5345) | 4044 (3180; 5233) | 0.452 | <0.001 |
N=100. Marker distribution is given as median (IQR). Correlations are Pearson’s partial correlation coefficient, adjusted for batch. All markers in experiment I were correlated with the same markers in experiment II. FI: fluorescence intensity. P16INK4a: percentage of p16INK4a positive cells; TAF (telomere associated foci): percentage of nuclei with ≥1 TAF/nucleus; ROS: mean fluorescence intensity peak reactive oxygen species; SAβ-gal: median fluorescence intensity peak senescence-associated β galactosidase.
Senescence markers and their correlations between short-term versus long-term experiments (2A).
| Distribution of markers | ||||
| Short-term experiment | Long-term experiment | Correlation coefficient | P-value | |
| ROS, FI | 1559 (1356; 1734) | 1500 (1366; 2205) | 0.419 | 0.010 |
| SAβ-gal, FI | 2973 (2445; 3732) | 3452 (2905; 4660) | -0.009 | 0.959 |
| ROS, FI | 2095 (1753; 2324) | 1835 (1553; 2205) | 0.426 | 0.009 |
| SAβ-gal, FI | 4171 (3530; 5231) | 4090 (3417; 5205) | -0.006 | 0.972 |
N=40. Correlations are Pearson’s partial correlation coefficient, adjusted for batch. All mean markers of short-term experiments I and II were correlated with the same markers in the long-term experiment. FI: fluorescence intensity. ROS: mean fluorescence intensity peak reactive oxygen species; SAβ-gal: median fluorescence intensity peak senescence-associated β galactosidase.
Figure 1Correlation plots of the same senescence markers between duplicate experiments and between short-term versus long-term experiments. Each dot represents an individual donor, N=40-100. Uncorrected (not log transformed) data points are shown. P16INK4a: percentage of p16INK4a positive cells; TAF (telomere associated foci): percentage of nuclei with ≥1 TAF/nucleus; ROS: mean fluorescence intensity peak reactive oxygen species; SAβ-gal: median fluorescence intensity peak senescence-associated β galactosidase. For the between short-term and long-term experiment correlations, in vitro variables are the mean of short-term experiments.
Intra-individual correlations: in vitro senescence markers versus in situ p16INK4a positive human fibroblasts (3B).
| Coefficient | P-value | |
| p16INK4a | 0.064 | 0.655 |
| TAF | -0.030 | 0.835 |
| ROS | -0.097 | 0.498 |
| SAβ-gal | -0.042 | 0.772 |
| p16INK4a | 0.091 | 0.527 |
| TAF | 0.014 | 0.922 |
| ROS | -0.095 | 0.506 |
| SAβ-gal | 0.023 | 0.871 |
Values are depicted as Pearson's partial correlation coefficient, adjusted for batch. Data for in situ and in vitro senescence markers were available for N=52 donors. P16INK4a positive dermal fibroblasts: number of positive cells per 1mm2 dermis. All in vitro variables are the mean of short-term experiments. P16INK4a: % of p16 positive cells; ROS: mean fluorescence intensity peak; SAβ-gal: median fluorescence intensity peak; telomere-associated foci (TAF): % of nuclei with ≥1 53BP1 foci per nucleus, coinciding with telomeric DNA.
Figure 2Intra-individual correlations: . Each dot represents an individual donor, N=52. In vitro p16INK4a positivity: percentage of p16INK4a positive cells - mean of experiments I and II. In situ p16INK4a positivity: number of p16INK4a positive cells per 1mm2 dermis. Uncorrected (not log transformed) data points are shown.
Figure 3Explanation of hypotheses tested. TAF: telomere associated foci. ROS: reactive oxygen species. SAβ-gal: senescence-associated β galactosidase.